My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Arthritis Res Ther. 2007;9(1):R12.

    Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosis.

    Schilders G, Raijmakers R, Malmegrim KC, Vande Walle L, Saelens X, Vree Egberts W, van Venrooij WJ, Vandenabeele P, Pruijn GJ.

    Department of Biomolecular Chemistry, Nijmegen Center for Molecular Life Sciences, Institute for Molecules and Materials, Radboud University Nijmegen, Geert Grooteplein 26-28, Nijmegen, 6525 GA, The Netherlands. g.schilders@ncmls.ru.nl

    Abstract

    Recent studies have implicated the dying cell as a potential reservoir of modified autoantigens that might initiate and drive systemic autoimmunity in susceptible hosts. A number of subunits of the exosome, a complex of 3'-->5' exoribonucleases that functions in a variety of cellular processes, are recognized by the so-called anti-PM/Scl autoantibodies, found predominantly in patients suffering from an overlap syndrome of myositis and scleroderma. Here we show that one of these subunits, PM/Scl-75, is cleaved during apoptosis. PM/Scl-75 cleavage is inhibited by several different caspase inhibitors. The analysis of PM/Scl-75 cleavage by recombinant caspase proteins shows that PM/Scl-75 is efficiently cleaved by caspase-1, to a smaller extent by caspase-8, and relatively inefficiently by caspase-3 and caspase-7. Cleavage of the PM/Scl-75 protein occurs in the C-terminal part of the protein at Asp369 (IILD369 [see text] G), and at least a fraction of the resulting N-terminal fragments of PM/Scl-75 remains associated with the exosome. Finally, the implications of PM/Scl-75 cleavage for exosome function and the generation of anti-PM/Scl-75 autoantibodies are discussed.

    PMID: 17280603 [PubMed - indexed for MEDLINE]PMCID: PMC1860071Free PMC Article

    Supplemental Content

    Click here to read Click here to read

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    Write to the Help Desk